3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
2
Paraproteinemias
1
Amyloidosis
1
Alzheimer Disease
1
Interventions
Bortezomib
5
Dexamethasone
4
Lenalidomide
3
Granulocyte Colony-Stimulating Factor
3
fludarabine
2
filanesib
2
dacetuzumab
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
plerixafor
1
ofatumumab
1
isatuximab
1
fludarabine phosphate
1
ficlatuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tacrolimus
1
Rifaximin
1
Proteasome Inhibitors
1
Plasma Exchange
1
Mycophenolic Acid
1
KW-2478
1
Hsp90 inhibitor KU757
1
Erlotinib Hydrochloride
1
Denosumab
1
Cyclophosphamide
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Paraproteinemias
×
birtamimab
×
Clear all
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts